Form 4: Guardant Health CTO Sells Shares Under 10b5-1 Plan

Guardant Health's Chief Technology Officer, Darya Chudova, reported the sale of over 22,000 shares of common stock and a transfer of shares to a family trust.

Summary

• Darya Chudova, Chief Technology Officer of Guardant Health, Inc., reported transactions involving the company's common stock.
• On December 8, 2025, Chudova transferred 68,144 shares of common stock from direct ownership to The Chudova Family Trust, a change in ownership form with a price of $0.
• On the same date, Chudova sold 9,271 shares of common stock directly at a weighted average price of $106.0029 per share.
• Additionally, 13,664 shares held indirectly through The Chudova Family Trust were sold at a weighted average price of $105.0371 per share.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan, indicating they were pre-arranged.
• Following these transactions, Chudova beneficially owns 21,734 shares directly and 68,144 shares indirectly through The Chudova Family Trust.
• The filing also notes 488 shares acquired under the Guardant Health's Employee Stock Purchase Plan on May 14, 2023.

Sentiment

Score: 4

Explanation: The sale of a significant number of shares by a key executive, even under a 10b5-1 plan, typically generates a slightly negative sentiment as it reduces insider ownership. However, the pre-arranged nature mitigates the immediate negative impact compared to an unplanned sale.

Negatives

• Chief Technology Officer Darya Chudova sold a total of 22,935 shares of Guardant Health common stock.
• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces management's direct equity stake.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Transfer of 68,144 shares to The Chudova Family Trust, which is a related party transaction as it involves the reporting person's family trust.

Stakeholder Impact

• Shareholders may perceive the insider selling as a negative signal, potentially impacting investor confidence.
• Employees are not directly impacted by this specific filing, though general market sentiment could indirectly affect morale.

Key Dates

Recommendation

The Chief Technology Officer's sale of shares, while notable, was conducted under a pre-arranged 10b5-1 trading plan, which suggests the decision was not based on immediate, non-public negative information. However, significant insider selling can still be interpreted by the market as a reduction in management's conviction or a move to diversify personal wealth. Without additional fundamental company news, a 'hold' recommendation is appropriate to observe market reaction and future company performance.

Keywords

Guardant Health, GH, Darya Chudova, Insider Trading, Form 4, Stock Sale, CTO, Biotechnology, Medical Devices